CoChat

Trastuzumab (Herceptin) Enhances Class I-Restricted Antigen Presentation Recognized by HER-2/neu-Specific T Cytotoxic Lymphocytes

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

PURPOSE: Numerous examples from animal models and clinical trials showed that HER-2-derived peptides are naturally processed as a CTL epitope and can be recognized by tumor-specific CTLs in several tumors with HER-2 overexpression. The humanized anti-HER-2 monoclonal antibody, Herceptin, has been designed to specifically antagonize the HER-2 function by directing against the extracellular domain of the HER-2 protein. One of the actions of Herceptin includes the internalization and degradation of HER-2, which might increase the amount of HER-2-derived peptides available for loading to MHC class I. EXPERIMENTAL DESIGN: In the present study, we investigated how Herceptin treatment of HER-2-overexpressing targets affects lysis by HER-2-specific CTLs. RESULTS: We showed that Herceptin sensitized HER-2-overexpressing tumors to lysis by HLA-A2-restricted or HLA-A24-restricted CTLs, without any effect of the expression of MHC class I, costimulatory molecules, adhesion molecules, or TAP-1 on the targets. Furthermore, the enhancement of cytolytic activity with Herceptin was inhibited by addition of a specific proteasome inhibitor, lactacystin. CONCLUSIONS: These results suggested that Herceptin treatment might enhance the class I-restricted presentation of endogenous HER-2 antigen via the proteasome step, resulting in higher susceptibility of HER-2-overexpressing tumors to lysis by the HER-2-specific CTLs.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-03-0424

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Cited by

See all 59

Metadata

Authors
Kono, K., Sato, E., Naganuma, H., Takahashi, A., Mimura, K., Nukui, H., & Fujii, H.
Affiliations
  • University of Yamanashi Hospital (JP)
  • University of Yamanashi (JP)
  • 1First Department of Surgery, and
Venue
Clinical Cancer Research
Published
2004-04-01
Volume
10
Issue
7
Pages
2538-2544
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2144405588
Cited by
59
References
33
Citations by year
2023: 1 · 2022: 5 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 3 · 2016: 3 · 2015: 2 · 2014: 4 · 2013: 2 · 2012: 3
FWCI
1.68
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
trastuzumab, HER2/neu, MHC class I antigen presentation, cytotoxic T lymphocytes, CTL epitopes, tumor cell lysis, proteasome, lactacystin, HLA-A2, HLA-A24, HER2 overexpression
MeSH terms
Trastuzumab, Acetylcysteine, Antibodies, Monoclonal, Epitopes, Antigens, Neoplasm, Antineoplastic Agents, Cytotoxicity, Immunologic, Coloring Agents, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Genes, MHC Class I, Humans, T-Lymphocytes, Cytotoxic, Blotting, Western, Histocompatibility Antigens Class I, Apoptosis, Annexin A5, Erb-b2 Receptor Tyrosine Kinases, Cell Line, Tumor, Proteasome Endopeptidase Complex, Antibodies, Monoclonal, Humanized, Proteasome Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trastuzumab (Herceptin) Enhances Class I-Restricted Antigen Presentation Recognized by HER-2/neu-Specific T Cytotoxic Lymphocytes. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-03-0424
The paper
Kono, K., Sato, E., Naganuma, H., Takahashi, A., Mimura, K., Nukui, H., & Fujii, H. (2004). Trastuzumab (Herceptin) Enhances Class I-Restricted Antigen Presentation Recognized by HER-2/neu-Specific T Cytotoxic Lymphocytes. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-03-0424

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.